New Products, Emerging Markets Spur Pharmaceutical Growth For Bayer
This article was originally published in The Pink Sheet Daily
Executive Summary
During its recent earnings call, the German conglomerate pointed to five drugs recently launched or now awaiting regulatory approval as driving its pharmaceutical sales growth from 2013 to 2015, along with strengthening performance in emerging markets.